Literature DB >> 9433333

Mood stabilizer combinations: a review of safety and efficacy.

M P Freeman1, A L Stoll.   

Abstract

OBJECTIVE: Polypharmacy is common in the treatment of refractory bipolar disorder. The purpose of this article is to review the safety and efficacy of mood stabilizers in combinations.
METHOD: A manual and computer (MEDLINE) search was performed for combinations of the most commonly used mood-stabilizing agents.
RESULTS: The authors review safety and efficacy data on the more frequently encountered combinations of established and putative mood stabilizers.
CONCLUSIONS: There have been few controlled studies of the use of combinations of mood stabilizers. The interactions of such combinations are sometimes complex, often very useful, and potentially dangerous. One general rule that may reduce the risks of toxic drug interactions is to add medication to the patient's current regimen in modest doses and increase the dose slowly. The safest and most efficacious mood stabilizer combinations appear to be the mixtures of anticonvulsants and lithium, particularly valproate plus lithium. Once the mechanisms of the mood stabilizers are identified, it is possible that a more rational approach to combination therapy will emerge, based on synergism at the sites of action.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9433333     DOI: 10.1176/ajp.155.1.12

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  23 in total

1.  Guidelines for treatment of bipolar disorder.

Authors:  E B Dennehy
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 2.  Polytherapy in bipolar disorder.

Authors:  Daniel Lin; Hiram Mok; Lakshmi N Yatham
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Stem cell-based models and therapies: a key approach into schizophrenia treatment.

Authors:  Bagher Larijani; Peyvand Parhizkar Roudsari; Mahdieh Hadavandkhani; Sepideh Alavi-Moghadam; Mostafa Rezaei-Tavirani; Parisa Goodarzi; Forough Azam Sayahpour; Fereshteh Mohamadi-Jahani; Babak Arjmand
Journal:  Cell Tissue Bank       Date:  2021-01-02       Impact factor: 1.522

Review 4.  Interactions between antiepileptic and antipsychotic drugs.

Authors:  Frank M C Besag; David Berry
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Comparative efficacy and tolerability of drug treatments for bipolar disorder.

Authors:  S M Strakowski; M P DelBello; C M Adler
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

6.  Prevalence and predictors of prescription psychoactive medication use in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Tara M Brinkman; Nicole J Ullrich; Nan Zhang; Daniel M Green; Lonnie K Zeltzer; Karen M Lommel; Pim Brouwers; Deo Kumar Srivastava; Neelam Jain; Leslie L Robison; Kevin R Krull
Journal:  J Cancer Surviv       Date:  2012-12-08       Impact factor: 4.442

7.  Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects.

Authors:  Jagdev Sidhu; Sarah Job; Jonathan Bullman; Emma Francis; Richard Abbott; John Ascher; Jochen G W Theis
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

8.  Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care Physicians.

Authors:  Raphael J. Leo; Rajesh Narendran
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-06

9.  Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder.

Authors:  Arun Ravindran; Peter Silverstone; Denis Lacroix; Erno van Schaick; An Vermeulen; Jennifer Alexander
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition.

Authors:  Yan Leng; Min-Huei Liang; Ming Ren; Zoya Marinova; Peter Leeds; De-Maw Chuang
Journal:  J Neurosci       Date:  2008-03-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.